Production of immunoproximity catalysts

Claim 2

Process for producing an immunoproximity catalyst for a chemical reaction comprising the following steps:

Claim 3

(1) identifying a reactant and a catalytic group for said reaction;

Claim 4

(1) identifying a reactant and a catalytic group for said reaction;

Claim 5

(2) selecting a hapten which corresponds to the transition state complex of said reactant and said catalytic group;

Claim 6

(2) selecting a hapten which corresponds to the transition state complex of said reactant and said catalytic group;

Claim 7

(3) stimulating an immune response for production of antibodies by said hapten;

Claim 8

(3) stimulating an immune response for production of antibodies by said hapten;

Claim 9

(4) isolating purified antibodies from said immune response which are specific for said hapten;

Claim 10

(4) isolating purified antibodies from said immune response which are specific for said hapten;

Claim 11

(5) selecting a converting hapten which corresponds to the transition state complex of said reactant and said catalytic group;

Claim 12

(5) selecting a converting hapten which corresponds to the transition state complex of said reactant and said catalytic group;

Claim 13

(6) modifying said purified antibodies by the covalent attachment of the catalytic group while said catalytic group is specifically bound in binding site of said purified antibodies as a part of said converting hapten yielding antibody-catalytic group complexes which are active for said chemical reaction; and

Claim 14

(6) modifying said purified antibodies by the covalent attachment of the catalytic group while said catalytic group is specifically bound in binding site of said purified antibodies as a part of said converting hapten yielding antibody-catalytic group complexes which are active for said chemical reaction; and

Claim 15

(7) isolating the antibody-catalytic group complexes which are active for said chemical reaction from said modification.

Claim 16

(7) isolating the antibody-catalytic group complexes which are active for said chemical reaction from said modification.

Claim 17

The process of claim 1 wherein the reactant and catalytic group are represented by the formula the hapten is represented by the formula and the converting hapten is represented by the formula wherein X represents the nuclei and associated bonds which comprise the portion of the reactant altered in the reaction, and K represents the catalytic group, and Y represents the nuclei and associated bonds which comprise the analogous portion of the hapten molecule and the converting hapten molecule, and X and Y are related to each other in that Y has a higher valence state (see Table 2) and one or more bonds than X, and wherein Q and Q represent one or more substituents bonded to Y in the hapten and converting hapten, respectively, and wherein O cat represents the catalytic group and linker group bound to Y which is represented by the formula wherein K represents the catalytic group and L represents the linker group which is the remainder of the molecule which is used to form a permanent bond between the catalytic group and the antibody molecule, and wherein Q' cat represents an analog of the selected catalytic group and linker group, bound to Y, which is represented by the formula wherein K represents an unreactive analog of K which will form a stable bond with Y, and wherein L is an unreactive analog of L which induces the presence of a group in the antibody binding surface which is reactive with L and wherein R i , R 2 , and R and R 2 represent the residual chemical groups of the reactant, hapten, and converting hapten which do not participate in the catalytic event(s), and R 1 and R' 1 and R 2 and R are, respectively, substantially similar to each other.

Claim 18

The process of claim 2 wherein Q is selected from the group consisting of (a) a positive charge, (b) a negative charge, (c) polarity, (d) nonpolarity, and (e) substantial bulk.

Claim 19

The process of claim 2 wherein Q is selected from the group consisting of (a) a positive charge, (b) a negative charge, (c) pola rity, (d) non-polarity, (e) substantial bulk and ( f ) hydrogen.

Claim 20

The process of claim 2 wherein L contains a photo-activatable crosslinking group and L is an unreactive analog of said crosslinking group.

Claim 21

The process of claim 2 wherein L contains an electrophile group and L is a charged unreactive analog which induces a positioned, reactive nucleophile in the antibody binding surface.

Claim 22

The process of claim 2 wherein X is 0 or S, and Y is N or C.

Claim 23

The process of claim 2 wherein X is N, and Y is C.

Claim 24

The process of claim 2 wherein X is C, and Y is P.

Claim 25

The process of claim 3 wherein Q is a substituent comprising a positive charge selected from the group consisting of -NH 3 (+) , -NRH 2 (+) , -NR 2 H (+) , -NR 3 (+) and -SR 2 (+) .

Claim 26

The process of claim 3 wherein Q is a substituent comprising a negative charge selected from the group consisting of -CO 2 (-) , -PO 4 (-2) , -SO 4 (-2) , and -SO 3 (-) .

Claim 27

The process of claim 3 wherein Q is a substituent comprising polarity selected from the group consisting of

Claim 28

The process of claim 3 wherein Q is a substituent comprising non-polarity selected from the group consistinq of

Claim 29

The process of claim 3 wherein Q is a substituent comprising substantial bulk selected from the group consisting of -CO 2 (-) , -NH 2 , -NR 3 (+) , and -N0 2 .

Claim 30

The process of claim 2 wherein K is a catalyst selected from the group consisting of and a chelate containing Fe, Co, Cu, Pb, Ti, Al, Pd, B or Mg.

Claim 31

The process of claim 2 wherein K is a catalyst selected from the group consisting of and the uncomplexed chelate.

Claim 32

The process of claim 1 wherein the immune response is stimulated monoclonically and/or polyclonically.

Claim 33

The process of claim 1 wherein the chemical reaction is a general acid-base catalysis reaction.

Claim 34

The process of claim 1 wherein the chemical reaction is a nucleophilic catalysis reaction.

Claim 35

The process of claims 18 and 19 wherein the chemical reactions involve charge stabilization or destabilization in the transition state.

Claim 36

The process of claim 1 wherein the chemical reaction is an oxidation-reduction catalysis reaction.

Claim 37

The process of claim 18 wherein the general acid-base catalysis reaction is hydrolysis of protein molecules containing a specified sequence of amino acids.

Claim 38

The process of claim 18 wherein the general acid-base catalysis reaction is hydrolysis of polydeoxynucleotides or polyribonucleotides containing a specified sequence of nucleic acids.

Claim 39

The process of claim 19 wherein the nucleophilic catalysis reaction is hydrolysis of polydeoxynucleotides or polyrinonucleotides containing a specified sequence of nucleic acids.

Claim 40

The process of claim 20 wherein the charge stabilization or destabilization in the transition state is hydrolysis of polydeoxynucleotides or polyribonucleotides containing a specified sequence of nucleic acids.

Claim 41

The process of claims 18 and 19 wherein the catalysis reactions are hydrolysis of a drug selected from the group consisting of an ester, amide, and acetal bond.

Claim 42

The process of claims 18 and 19 wherein the catalysis reactions are hydrolysis of an acetal bond.

Claim 43

The process of claim 27 wherein the acetal bond is in a polysaccharide containing a specific sequence of sugars.

Claim 44

An immunoproximity catalyst made by the process of one or more of claims 1 to 28.